Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 5Classical hematology 2Other hematologic neoplasm 1

Conditions

Anemia 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2

Interventions

fludarabine phosphate 34Cyclophosphamide 34Peripheral Blood Stem Cell Transplantation 23Busulfan 22Mycophenolic Acid 21Cyclosporine 20Whole-Body Irradiation 19Tacrolimus 18Antilymphocyte Serum 18Melphalan 16Filgrastim 16Radiotherapy 15Methotrexate 14fludarabine 12Cord Blood Stem Cell Transplantation 12Methylprednisolone 10Cytarabine 10Etoposide 8sargramostim 6Granulocyte Colony-Stimulating Factor 5Cyclosporins 5Alemtuzumab 4thymoglobulin 3merphos 3Tretinoin 3Thiotepa 3Thalidomide 3Sirolimus 3Rituximab 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × luspatercept × Classical hematology × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡